Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021 or the TRANSPLANT Act of 2021 This bill modifies and reauthorizes through FY2026 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. The bill also requires the Department of Health and Human Services to conduct a periodic review of the science of using adult stem cells and birthing tissues in therapeutic treatments. In addition, the Government Accountability Office must report on the regenerative medicine workforce.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2022 · fourth_quarter · Labor Issues/Antitrust/Workplace
S. 225, the Competition and Antitrust Law Enforcement Reform Act of 2021; S. 1388, the Prescription Pricing for the People Act of 2021; H.R. 603 / S. 53, the Raise the Wage Act of 2021; H.R. 7, the Paycheck Fairness Act; Promoting Competition in the American Economy Executive Order; UnitedHealth Group proposed merger of Change Healthcare; Unfair Competition and Anticompetitive Contract Terms; Occupational exposure to COVID-19 and vaccine mandates; FTC 6(b) Study of Pharmacy Benefit Managers; S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022; S. 288/ H.R. 3843, the Merger Filing Fee Modernization Act of 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S575)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $320,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Occupational Safety & Health Administration (OSHA), SENATE, White House Office
2021 · second_quarter · Medical/Disease Research/Clinical Labs
Healthcare research and development related issues, as follows: Commerce, Justice, Science, and Related Agencies Appropriations Act, FY2022 Department of Defense Appropriations Act, FY2022, Medical research issues Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2022 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, FY2022 Monitor the following: H.R.941/S.288, Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021, Reauthorization related issues Public Law 117-2, American Rescue Plan Act of 2021, Endowment Tax issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Donor recruitment and transplant services H.R.941/S.288, Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies (TRANSPLANT) Act of 2021, generally COVID-19 Public Health Emergency, International to US Travel Restrictions Transplant program related issues Monitor Healthcare related issues, as follows: Public Law 116-260, Consolidated Appropriations Act, 2021, Division M, Coronavirus Response and Relief Supplemental Appropriations Act, 2021; and Division N, Additional Coronavirus Response and Relief Payment Coverage issues Public Law 117-2 American Rescue Plan Act of 2021
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2021 · first_quarter · Medical/Disease Research/Clinical Labs
H.R.941/S.288, Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2021, Reauthorization related issues Healthcare research and development related issues, as follows: Department of Defense Medical research issues Energy and Water Development and Related Agencies Appropriations Act, FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2022 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, FY2022 Monitor Public Law 117-2, American Rescue Plan Act of 2021, Endowment Tax issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
H.R. 941/S. 288, TRANSPLANT Act of 2021; Appropriations for the National Institutes of Health and support for an outcomes database for adult cellular therapies
Client expense: Not reported · Firm income: Not reported
| Democratic |
| MN |